title: Efficacy of 5-day continuous lidocaine infusion for the treatment of refractory complex regional pain syndrome.
abstract: OBJECTIVE
  Chronic regional pain syndrome (CRPS) is a severe pain condition that usually results from an injury or surgical procedure. The pain in CRPS often spreads from the site of injury, and with time becomes refractory to conventional therapy. The present study was undertaken to evaluate the effects of 5-day continuous intravenous lidocaine treatment in patients afflicted with CRPS.
  
  
  METHODS
  Intravenous lidocaine was administered in an escalating dose schedule to 49 severely affected CRPS patients in a monitored setting over 5 days. Evaluation of pain parameters and other signs and symptoms of CRPS were obtained during the infusion and at 1, 3, and 6 months following therapy.
  
  
  RESULTS
  The majority of patients demonstrated a significant decrease in pain parameters and other symptoms and signs of CRPS. The pain reduction lasted an average of 3 months. Lidocaine may be particularly effective for thermal and mechanical allodynia. Less clinically significant effects were documented on the motor aspects of the syndrome.
  
  
  CONCLUSIONS
  Intravenous lidocaine administration titrated to 5 mg/L demonstrated: 1) a significant decrease in mechanical and thermal allodynia for three months, 2) lessened associated inflammatory components of CRPS, and 3) only minimal side effects and no severe complications.
authors.affiliation: Department of Neurology, Drexel University College of Medicine, Philadelphia, Pennsylvania 19111-1839, USA. robert.schwartzman@drexelmed.edu
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Schwartzman
authors.forename: Mona
authors.initials: M
authors.lastname: Patel
authors.forename: John R
authors.initials: JR
authors.lastname: Grothusen
authors.forename: Guillermo M
authors.initials: GM
authors.lastname: Alexander
mesh_terms: D000293:Adolescent; D000328:Adult; D000779:Anesthetics, Local / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D020918:Complex Regional Pain Syndromes / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008012:Lidocaine / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D000779:Anesthetics, Local; D008012:Lidocaine